CD28 and neoplasm: PD-L1 CCR, which includes the CD28 costimulatory domain, can be used to design logic-gated CARs and be likely to enhance the safety profile of CAR-T cells and improve their efficacy either when the low-affinity CAR is used or the tumor cells express low-level TAAs.